These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23725475)

  • 21. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
    Carone D; Caropreso C; Vitti A; Chiappetta R
    J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).
    Fatemi H; Bilger W; Denis D; Griesinger G; La Marca A; Longobardi S; Mahony M; Yin X; D'Hooghe T
    Reprod Biol Endocrinol; 2021 May; 19(1):68. PubMed ID: 33975610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of exogenous supplementation with luteinizing hormone during controlled ovarian hyperstimulation on the results of IVF cycle].
    Toporcerová S; Hredzák R; Ostró A; Zdilová V; Potoceková D
    Ceska Gynekol; 2005 May; 70(3):187-91. PubMed ID: 16047921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outlook: who needs LH in ovarian stimulation?
    Alviggi C; Clarizia R; Mollo A; Ranieri A; De Placido G
    Reprod Biomed Online; 2006 May; 12(5):599-607. PubMed ID: 16790105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between mutations of the luteinizing hormone β subunit and female infertility.
    Du JW; Xu KY; Fang LY; Qi XL
    Mol Med Rep; 2012 Feb; 5(2):473-6. PubMed ID: 22108961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer.
    Onagawa T; Shibahara H; Ayustawati ; Machida S; Hirano Y; Hirashima C; Takamizawa S; Suzuki M
    Gynecol Endocrinol; 2004 Jun; 18(6):335-40. PubMed ID: 15497496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
    Bühler KF; Fischer R
    Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET.
    Drakakis P; Loutradis D; Kallianidis K; Liapi A; Milingos S; Makrigiannakis A; Dionyssiou-Asteriou A; Michalas S
    Eur J Obstet Gynecol Reprod Biol; 2005 Jul; 121(1):77-80. PubMed ID: 15989987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
    Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
    Conforti A; Esteves SC; Humaidan P; Longobardi S; D'Hooghe T; Orvieto R; Vaiarelli A; Cimadomo D; Rienzi L; Ubaldi FM; Zullo F; Alviggi C
    Reprod Biol Endocrinol; 2021 Jun; 19(1):91. PubMed ID: 34154604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of LH and FSH in ovarian function.
    Howles CM
    Mol Cell Endocrinol; 2000 Mar; 161(1-2):25-30. PubMed ID: 10773387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
    Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
    Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.